Oryzon Genomics (STU:ORN) Cyclically Adjusted PB Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ORN Oryzon Genomics SA STU:ORN
40 GF Score
Price €2.96
View Full Analysis

What is Oryzon Genomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oryzon Genomics  (STU:ORN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oryzon Genomics Cyclically Adjusted PB Ratio Related Terms


Oryzon Genomics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Cyclically Adjusted PB Ratio Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.05 2.25

Oryzon Genomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 2.18 2.25 1.97 0.00

STU:ORN vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Oryzon Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Cyclically Adjusted PB Ratio falls into.


STU:ORN
40GF Score
Oryzon Genomics SA STU:ORN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oryzon Genomics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Oryzon Genomics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.461/130.5100*130.5100
=1.461

Current CPI (Jun. 2026) = 130.5100.

Oryzon Genomics Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.865 99.737 1.132
201612 0.820 101.842 1.051
201703 0.775 100.896 1.002
201706 1.099 101.848 1.408
201709 1.063 101.524 1.366
201712 1.028 102.975 1.303
201803 0.994 102.122 1.270
201806 1.042 104.165 1.306
201809 0.883 103.818 1.110
201812 1.173 104.193 1.469
201903 1.140 103.488 1.438
201906 1.152 104.612 1.437
201909 1.376 103.905 1.728
201912 1.355 105.015 1.684
202003 1.137 103.469 1.434
202006 1.472 104.254 1.843
202009 1.461 103.521 1.842
202012 1.439 104.456 1.798
202103 1.405 104.857 1.749
202106 1.420 107.102 1.730
202109 0.001 107.669 0.001
202112 1.351 111.298 1.584
202203 1.313 115.153 1.488
202206 1.329 118.044 1.469
202209 1.294 117.221 1.441
202212 1.295 117.650 1.437
202303 1.241 118.948 1.362
202306 1.363 120.278 1.479
202309 1.349 121.343 1.451
202312 1.343 121.300 1.445
202403 1.321 122.762 1.404
202406 1.375 124.409 1.442
202409 1.364 123.121 1.446
202412 1.362 124.753 1.425
202503 1.101 125.531 1.145
202506 1.474 127.251 1.512
202509 1.481 126.840 1.524
202512 1.520 128.400 1.545
202603 1.532 129.860 1.540
202606 1.461 130.510 1.461

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oryzon Genomics Business Description

Other Exchanges ORYZF:USA0RDB:UKORY:Spain
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
40GF Score

Get the complete analysis for STU:ORN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.96
Price